Beyond the Skin: How Inflammation Connects Dermatologic Disease
Targeted biologics may offer steroid-sparing benefits in eligible patients, particularly when chronic
Faculty cautioned, however, that controlling existing atopic disease does not establish that biologic therapy prevents the development of future atopic conditions.
The Gut-Skin Connection in Psoriasis and Atopic Disease
The next presentation examined the relationship between inflammatory skin conditions and gastrointestinal disease, with particular attention to the gut microbiome and shared inflammatory pathways.
Faculty discussed how intestinal dysbiosis, altered immune signaling, and changes in intestinal permeability have been investigated as potential contributors to systemic inflammation.
Psoriasis, hidradenitis suppurativa, and
The presenter explained that although certain cytokine pathways contribute to both dermatologic and gastrointestinal inflammation, inhibiting a particular pathway may produce different effects depending on the affected organ.
Although IL-17 inhibitors are effective treatments for psoriasis, this pathway also contributes to intestinal barrier function. In susceptible patients, IL-17 inhibition may exacerbate existing IBD or be associated with new gastrointestinal inflammatory symptoms.
Faculty encouraged clinicians to assess for relevant gastrointestinal symptoms and consider collaboration with gastroenterology when selecting systemic therapies.
The discussion also addressed the relationship between AD and EoE, which share type 2 inflammatory mechanisms involving IL-4 and IL-13.
For dermatology clinicians, recognizing symptoms such as dysphagia, food impaction, and food avoidance may help identify patients who warrant further gastrointestinal evaluation.
Recognizing Metabolic Liver Disease in Patients With Psoriasis
Another focus of the gastrointestinal discussion was metabolic dysfunction-associated steatotic liver disease (
Faculty described the association between psoriasis and metabolic liver disease, emphasizing the importance of considering metabolic comorbidities when evaluating patients with chronic inflammatory conditions.
The presentation reviewed how metabolic dysfunction can contribute to hepatic fat accumulation, inflammation, and progressive fibrosis.
In some patients, MASLD may progress to metabolic dysfunction-associated steatohepatitis (MASH), a more inflammatory form of liver disease.
The presenter encouraged dermatology clinicians to recognize patients who may benefit from further evaluation based on metabolic risk factors and relevant clinical findings.
This discussion reinforced the importance of considering cardiovascular and metabolic health alongside cutaneous disease activity when developing long-term management plans.
Balancing Skin Cancer Risk With Inflammatory Disease Control
The session also examined the complex relationship between chronic inflammatory disease, immunomodulatory treatments, and skin cancer risk.
A medical oncologist specializing in skin cancer management discussed how treatment decisions may become particularly challenging when patients require both inflammatory disease control and cancer treatment.
The presentation reviewed differences in skin cancer risk associated with various therapeutic approaches, including conventional immunosuppressants, biologics, and historical phototherapy regimens.
Faculty discussed the importance of cumulative treatment exposure, particularly with psoralen plus ultraviolet A (
The oncologist also addressed the challenges of treating patients with autoimmune conditions who develop advanced skin cancers.
Consequently, treatment decisions may require balancing the urgency of cancer management against the possibility of worsening inflammatory disease.
Clinical scenarios involving patients with longstanding psoriasis illustrated how previous treatment exposure, current disease control, and cancer severity may influence therapeutic decisions.
The presenter emphasized that these cases require close communication among dermatologists, oncologists, and other treating specialists rather than isolated decision-making.
Measuring Quality of Life Beyond Skin Clearance
The final presentation shifted attention toward patient-centered communication and the importance of measuring treatment outcomes beyond visible disease improvement.
A dermatology and psychiatric nurse practitioner discussed how chronic inflammatory skin diseases can affect sleep, mood, daily functioning, relationships, and overall quality of life.
The presentation also examined the relationship between chronic stress, neuroimmune signaling, and the
Faculty noted that persistent pruritus can involve changes in neural pathways associated with itch perception and reward, illustrating why chronic scratching should not be viewed simply as a behavioral issue.
The presenter emphasized that improvements in cutaneous symptoms do not necessarily resolve the psychological burden associated with chronic disease.
“Just because a patient’s skin is clear doesn’t necessarily mean that they’re not going to be depressed anymore, that they’re not going to be anxious anymore,” the presenter said.
To better capture patient experiences, faculty discussed incorporating validated measures such as the Dermatology Life Quality Index (DLQI), along with screening tools for depression and anxiety.
These assessments may help clinicians evaluate changes in quality of life over time and identify concerns that might otherwise go unrecognized.
However, the presenter emphasized that questionnaires should complement, rather than replace, direct conversations with patients.
Asking patients what they hope to regain through treatment, whether improved sleep, greater confidence, or the ability to participate in daily activities, can help clinicians establish more meaningful therapeutic goals.
Advancing Multidisciplinary, Patient-Centered Care
The session concluded by reinforcing the importance of recognizing inflammatory skin diseases as part of a broader clinical picture.
Shared immune pathways can connect dermatologic conditions with respiratory, gastrointestinal, metabolic, and other systemic disorders, creating opportunities for coordinated treatment while introducing additional considerations for therapeutic selection.
Faculty emphasized that clinicians should evaluate comorbidities, assess medication risks, and collaborate with other specialties when necessary.
Equally important, treatment success should be measured through both clinical outcomes and patient-reported improvements in sleep, functioning, mental health, and quality of life.
As the management of inflammatory skin diseases becomes increasingly complex, the opening session of DermNexus 2026 Day 2 highlighted the importance of moving beyond skin clearance toward comprehensive, individualized care that addresses the full burden of disease.